Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
IDEA AG |
---|---|
Information provided by: | IDEA AG |
ClinicalTrials.gov Identifier: | NCT00316784 |
The study objective is the eluciation of the dose-response function in efficacy (and possibly safety) in order to determine an optimal dose with respect to efficacy and safety. The study is designed with three dose levels and one placebo control.
Condition | Intervention | Phase |
---|---|---|
Osteoarthritis; Knee |
Drug: IDEA-033 (and rescue medication) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled Evaluation of Dose Related Safety and Efficacy of Epicutaneously Applied IDEA-033 for 3 Months Treatment of OA of the Knee Followed by a Double-Blind, Dose-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 for 12 Weeks Treatment of OA of the Knee |
Estimated Enrollment: | 704 |
Study Start Date: | July 2005 |
Estimated Study Completion Date: | May 2006 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CL-033-III-02/E |
Study First Received: | April 19, 2006 |
Last Updated: | August 8, 2006 |
ClinicalTrials.gov Identifier: | NCT00316784 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
osteoarthritis; knee; IDEA-033 |
Osteoarthritis, Knee Signs and Symptoms Musculoskeletal Diseases Osteoarthritis |
Joint Diseases Arthritis Rheumatic Diseases |